FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Wall Street analysts expect Regeneron (REGN) to post quarterly earnings of $8.76 per share in its upcoming report, which indicates a year-over-year decline of 8.3%. Revenues are expected to be $3.25 ...

Capital International Ltd. CA boosted its Regeneron Pharmaceuticals holdings by 14.5% in Q4, now holding nearly $29.2 million ...

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is scheduled to begin operations this year.

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

Bank of America decided to rain on Regeneron's parade, lowering its price target from $575 to $547, tagging it with an ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Explore how Trump's tariffs affect corporate strategies and consumer prices in America amid changing import dynamics.

Major U.S. drugmakers, including Eli Lilly and Johnson & Johnson, have recently announced additional investments in their U.S ...

Major U.S. drugmakers, including Eli Lilly and Johnson & Johnson , have announced additional investments in their U.S. production as they grapple with the threat of drug import duties from President ...

At Reuters Events Pharma 2025 in Barcelona, industry leaders united to reimagine medical communications amidst content ...